BLOG

endpoints

Heat Biologics goes back to San Antonio to build a research and manufacturing facility

Heat’s pipeline features candidates for immuno-oncology, infectious diseases and Covid-19. HS-110 has completed its Phase II trial to treat non-small cell lung cancer, and solid tumor treatment PTX-35 and T cell activator HS-130 are in Phase I trials. The new Scorpion site will support new drugs from discovery through clinical trials.